维普期刊资源整合服务平台（V6.5）

27篇 您的检索式：作者名="BEST JH"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Incidence and Eong-term cost of steroid- related side effects after renal transplantation 显示文摘	Veenstra DL Best JH Hornberger J	1999	Am J Kidney Dis1999，33，5：	1
2	Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon- like peptide I(GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database显示文摘	Best JH Hoogwerf B J Herman WH	2011	Diabetes Care2011，34，1：	1
3	Risk of cardiovasculardisease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or otherglucose-lowering therapies a retrospective analysis of the LifeLinkdatabase显示文摘	Best JH Hoogwerf BJ Herman WH	2011	Diabetes Care2011，34，1：	1
4	Prevalence of CYP 2 C 19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in native Americans 显示文摘	OESTREICH JH BEST LG DOBESH PP	2014	Am Heart J2014，167，3：	1
5	Effects of entericbacterial and cyanobacterial lipopolysaccharides,and ofmicrocystin-LR,on glutathione S-transferase activities in zebrafish(Danio rerio)显示文摘	Best JH Pflugmacher S Wiegand C	2002	Aquat Toxicol2002，60，34：	1
6	Economic evaluation of capecitabine as adju- vant or metastatic therapy in eolorectal cancer显示文摘	Best JH Garrison LP	2010	Expert Rev Phar- macoecon Outcomes Res2010，10，2：	1
7	Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifeline database 显示文摘	Best JH Hoogwerf B J Herman WH	2011	Diabetes Care2011，34，1：	1
8	Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon- like peptide I(GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the Life Link database显示文摘	Best JH Hoogwerf B J Herman WH	2011	Diabetes Care2011，34，1：	1
9	Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans 显示文摘	Oestreich JH Best LG Dobesh PP	2014	Am Heart J2014，167，：	1
10	The cost effectiveness of mycophenolate mofetil in the first year after prima-ry cadaveric transplant显示文摘	SULLIVAN SD GARRISON LP JR BEST JH	1997	J Am Society Nephrol1997，，8：	1
11	Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies:a retrospective analysis of the LifeLink database显示文摘	Best JH Hoogwerf BJ Herman WH		0，，01：	1
12	Risk of cardio- vascular disease events in patients with type 2 diabetes pre- scribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database 显示文摘	Best JH Hoogwerf B J Herman WH	2011	Diabetes Care2011，34，1：	1
13	Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database显示文摘	Best JH Hoogwerf BJ Herman WH	2011	Diabetes Care2011，34，：	1
14	Incidence and long-term cost of steroid-related side effects after renal transplantation显示文摘	Veenstra DL Best JH Hornberger J	1999	Am J Kidney Dis1999，33，5：	1
15	Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans 显示文摘	Oestreich JH Best LG I)obesh PP	2014	Am Heart J2014，167，3：	1
16	Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone af- ter 26 weeks of treatment 显示文摘	Best JH Rubin RR Peyrot M	2011	Diabetes Care2011，34，2：	1
17	Risk of cardiovascular diseaseevents in patients with type 2 diabetes prescribed the glucagon-like pep-tide 1(GLP-1)receptor agonist exenatide twice daily or other glucoselowering therapies:a retrospective analysis of the LifeLink database显示文摘	Best JH Hoogwerf BJ Herman WH	2011	Diabetes Care2011，34，1：	1
18	Risk of cardio- vascular disease event in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies : a retrospective analysis of the life link database 显示文摘	Best JH Hoogwerf BJ Herman WH	2011	Diabetes Care2011，34，1：	1
19	Cost utility in the United States of rituximab plus cyelophosphamide, doxorubicin, vincristine,and prednisone for the treatment of elderly patients with diffuse large B-celt lymphoma显示文摘	Hornberger JC Best JH	2005	Cancer2005，103，8：	1
20	Next-generation field guides显示文摘	Farnsworth EJ Chu M Kress WJ Neill AK Best JH Pickering J Stevenson RD Courtney GW Van Dyk JK Ellison AM	2013	BioScience2013，63，11：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示